Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
AKR1B10 İfadeleyen Kolorektal Kanser Hücrelerinde Metabolik Yeniden Programlanma
Date
2022-03-01
Author
Güderer, Ismail
Seza, Esin Gülce
Ermiş, Çağdaş
Banerjee, Sreeparna
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
104
views
0
downloads
Cite This
Metabolic Rewiring in AKR1B10 Expressing Colorectal Cancer CellsAKR1B10 is a nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-dependent reductase enzyme that belongs to the Aldo-Keto Reductase (AKR) 1B subfamily. Although it shares ~70% similarity in amino acid sequence with the AKR1B1 enzyme, unlike AKR1B1, AKR1B10 does not show reductase activity towards glucose. It instead reduces carbonyl-containing compounds such as retinals and lipid-derived cytotoxic aldehydes. We have previously shown that colorectal tumors with high expression of AKR1B1 and low expression of AKR1B10 (AKR1B1HIGH/AKR1B10LOW) could be assigned to Consensus Molecular Subtype (CMS) 4, were associated with enhanced mesenchymal properties and showed significantly poor prognosis. In contrast, the AKR1B1LOW/AKR1B10HIGH signature was primarily epithelial, belonged to CMS3, and was characterized by the inhibition of metabolic pathways associated with biomass production and cell proliferation (Demirkol Canlı et al., 2020). In the current study, we have focused on metabolic reprogramming in AKR1B10HIGH tumors and cell lines. Cancer cells undergo extensive metabolic reprogramming to fuel cellular growth and proliferation, including increased fatty acid synthesis (FAS). Fatty acid oxidation (FAO) also appears to be essential to supply high amounts of ATP needed by cancer cells. However, what activates FAS versus FAO in cancer cells is a subject of continuing interest. Analyses of publicly available datasets of colorectal tumors showed that AKR1B10 expression, along with FAO genes, was decreased in primary colorectal tumors compared to normal tissues. Furthermore, gene set enrichment analysis of the TCGA-COAD tumors classified into high vs. low AKR1B10 expressing showed that AKR1B10HIGH tumors were enriched in the gene ontology (GO) terms “regulation of lipid metabolism” and “cellular lipid catabolic process”. Stable ectopic expression of AKR1B10 in RKO cells showed robust phosphorylation of Acetyl CoA Carboxylase (ACC). ACC is a regulatory enzyme that undergoes inhibitory phosphorylation when FAO is activated while hypophosphorylation of ACC is associated with increased FAS. Taken together, our findings reveal for the first time that in addition to its role as an oxidoreductase, AKR1B10 expression may regulate lipid metabolism, favoring FAO rather than FAS in colorectal cancer.Publication: Demirkol Canlı, S., Seza, E. G., Sheraj, I., Gömçeli, I., Turhan, N., Carberry, S., Prehn, J., Güre, A. O., & Banerjee, S. (2020). Carcinogenesis, 41(9), 1219–1228
URI
https://www.transcoloncan.eu/media/upload/pdf/abstract-book-torino-2022_update_26_13_151.pdf
https://hdl.handle.net/11511/100090
Collections
Department of Biology, Article
Suggestions
OpenMETU
Core
AKR1B10 İfadeleyen Kolorektal Kanser Hücrelerinde Metabolik Yeniden Programlanma
Güderer, İsmail; Seza, Esin Gülce; Ermiş, Çağdaş; Banerjee, Sreeparna (2022-03-07)
Metabolic Rewiring in AKR1B10 Expressing Colorectal Cancer Cells AKR1B10 is a nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-dependent reductase enzyme that belongs to the Aldo-Keto Reductase (AKR) 1B subfamily. Although it shares ~70% similarity in amino acid sequence with the AKR1B1 enzyme, unlike AKR1B1, AKR1B10 does not show reductase activity towards glucose. It instead reduces carbonyl-containing compounds such as retinals and lipid-derived cytotoxic aldehydes. We have previously shown that ...
Investigation of docetaxel and doxorubicin resistance in mcf-7 breast carcinoma cell line
Darcansoy İşeri, Özlem; Gündüz, Ufuk; Department of Biotechnology (2009)
Multidrug resistance phenotype of tumor cells describes resistance to wide range of structurally unrelated anticancer agents and is a serious limitation to effective chemotherapy. It is a multifactor yet not fully elucidated phenomenon by the involvement of diverse cellular pathways. Aim of this study was to investigate the resistance mechanisms developed against docetaxel and doxorubicin that are widely used in the treatment of breast cancer in model cell line MCF-7. Resistant sublines were developed by ap...
Evaluation of functional changes in akr1b1 and akr1b10 overexpressing colorectal cancer cell lines
Güderer, İsmail; Banerjee, Sreeparna; Department of Biology (2021-2-15)
Aldo-keto reductases (AKRs) are nicotinamide adenine dinucleotide phosphate (NADPH)-dependent enzymes with diverse cellular metabolism functions. AKR1B1 and AKR1B10 are two of the most studied enzymes in the AKR family. AKR1B1 reduces excess glucose into sorbitol using reducing electrons from NADPH, and the hyperactivation of the AKR1B1 pathways is associated with oxidative stress and cell death. AKR1B10 is a poor reductant of glucose but is a vital enzyme that can metabolize retinol and many other drugs an...
ASSOCIATION OF FLT3 AND NPM1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH METABOLOMIC PATTERNS DETERMINED BY MASS SPECTROMETRY
Gerekci Yeşilyurt, Selin; Özen, Can; Özçubukçu, Salih; Department of Biochemistry (2022-8-29)
Acute Myeloid Leukemia is a hematological cancer with high phenotypic and genotypic heterogeneity. Patients diagnosed with AML are categorized into risk groups based on cytogenetic and molecular abnormality tests, which determine the specific treatment regimes. Since risk status determination takes significant amount of time and some emergency patients require immediate treatment, a method to provide fast clinical data that will be the basis for initial treatment regime is needed in the medical commun...
Molecular mechanisms of vincristine and paclitaxel resistance in mcf-7 cell line
Demirel Kars, Meltem; Gündüz, Ufuk; Department of Biotechnology (2008)
Resistance to broad spectrum of chemotherapeutic agents in cancer cell lines and tumors has been called multiple drug resistance (MDR). In this study, the molecular mechanisms of resistance to two anticancer agents (paclitaxel and vincristine) in mammary carcinoma cell line MCF-7 were investigated. MCF-7 cells were selected in the presence of paclitaxel and vincristine by stepwise dose increments. The cell viability and growth profiles of resistant sublines were examined. As the resistance indices increased...
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
I. Güderer, E. G. Seza, Ç. Ermiş, and S. Banerjee, “AKR1B10 İfadeleyen Kolorektal Kanser Hücrelerinde Metabolik Yeniden Programlanma,” 2022, Accessed: 00, 2022. [Online]. Available: https://www.transcoloncan.eu/media/upload/pdf/abstract-book-torino-2022_update_26_13_151.pdf.